Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for...

Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for...

Anticancer Agent LENVIMA A Approved for Additional Indication of Unresectable Hepatocellular Carcinoma in Japan, First Approval Worldwide for LENVIMA for HCC )--Eisai Co., Ltd. and Merck , known as MSD outside the United States and Canada, today announced that the multiple receptor tyrosine kinase inhibitor LENVIMAA has been approved in Japan for unresectable hepatocellular carcinoma . This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front line treatment of HCC in approximately 10 years.

from Biotech News